Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: achievelifesciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $12.00 | Buy | Rodman & Renshaw |
| 9/27/2024 | $20.00 | Strong Buy | Raymond James |
| 5/10/2023 | $8.00 → $20.00 | Buy | Maxim Group |
| 10/4/2021 | $25.00 | Buy | Alliance Global Partners |
| 6/23/2021 | $23.00 | Outperform | Oppenheimer |
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00
Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00
Maxim Group reiterated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $20.00 from $8.00 previously
Alliance Global Partners initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $25.00
Oppenheimer initiated coverage of Achieve Life Sciences with a rating of Outperform and set a new price target of $23.00
Maxim Group resumed coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $21.00
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
DEF 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
10-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
S-8 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5, 2025, in New York City. Rick Stewart, Chief Executive Officer of Achieve, will present on Wednesday, June 4, 2025, at 5:30 PM EDT. A live webcast and replay of the presentation will be available on the Investor section of the company's website. For more information, please contact your
SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco, CA. Presentation Details: Title: Cytisinicline Reduces Cravings and Nicotine Intake in People Who Smoke and Don't Quit CompletelySession: C95 – Public Health and Policy Relevant ResearchFormat: Mi
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-3 was the
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and provide an update on the cytisinicline development program on Tuesday, March 11, 2025, at 8:30 AM EDT. To access the webcast, please use the following link 4Q24 Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817 (International) and refer
SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Rick Stewart, Chief Executive Officer of Achieve, will be presenting today at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 10:00 a.m. EST. For more information, please contact your banking representative directly or visit the Achieve Life Sciences Investor Relations website. About Achieve Life Sciences, Inc. Achieve Life Science
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Data Safety Monitoring Committee (DSMC) has recently completed its second independent review of the ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigaret
SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea
SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, information technology, legal and other key administrative functions, ensuring effective planning and execution to support organizational objectives. "Mark's extensive financial, strategic, and opera
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. "I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will p
SEATTLE and VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Vaughn Himes to the company's Board of Directors, effective immediately. "We are pleased to welcome Dr. Himes to the Achieve board," commented Rick Stewart, Executive Chairman of the Board of Directors. "As we continue to advance the cytisinicline clinical development program towards commercialization, Dr. Himes' deep background and expertise will offer invaluable
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company's Board of Directors, effective immediately. "We are excited to welcome Dr. Martell and Dr. Jacobs to the board", commented Rick Stewart, Achieve's Executive Chairman of the Board of Directors. "Dr. Martell's clinical development experience compliments that of Dr. Jacobs, providing the company with depth of knowledge, particularly in
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and provide an update on the cytisinicline development program on Tuesday, March 11, 2025, at 8:30 AM EDT. To access the webcast, please use the following link 4Q24 Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817 (International) and refer
SEATTLE and VANCOUVER, British Columbia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced its financial results for the third quarter of 2024 and provided an update on its cytisinicline development program. Recent Highlights Completed enrollment in the Phase 3 ORCA-OL clinical trial and announced first Data Safety Monitoring Committee Meeting successfully conductedPresented at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) Joint Public Meeting on smokin
SEATTLE and VANCOUVER, British Columbia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced it will report its third quarter 2024 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 7, 2024, at 4:30 PM EST. To access the webcast, please use the following link: 3Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817 (International) and referencing
SEATTLE and VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its financial results for the second quarter of 2024 and provided an update on its cytisinicline development program. Recent Highlights The FDA granted Breakthrough Therapy designation for cytisinicline treatment of nicotine e-cigarette, or vaping, cessationCompleted refinancing and extended the maturity date of outstanding term loans with Silicon Valley Bank (SVB)Joined the U.S. Russell 3000® and Rus
SEATTLE and VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2024 financial results and provide an update on the cytisinicline development program on Tuesday, August 13, 2024, at 4:30 PM EDT. To access the webcast, please use the following link: 2Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 137473
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT. To access the webcast, please use the following link: 1Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 13744142.
SEATTLE and VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth quarter and year-end 2023 financial results and provide an update on the cytisinicline development program on Thursday, March 28, 2024, at 4:30 PM EST. To access the webcast, please use the following link 4Q23 Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13D/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)